Allergen immunotherapy in allergic rhinitis: current use and future trends

References

• Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. DOI:10.1016/S0140-6736(06)69283-0.
   PubMed Web of Science ®Google Scholar
• Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110–124. DOI:10.1111/j.1399-3038.2007.00601.x
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–2170. DOI:10.1016/S0140-6736(07)60946-5.
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948. DOI:10.1111/j.1398-9995.2007.01451.x.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Gerth van Wijk R, Eichler I, et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol. 2012;23(4):300–306. DOI:10.1111/j.1399-3038.2012.01313.x.
   PubMed Web of Science ®Google Scholar
• Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006;117(6):1470–1476. DOI:10.1016/j.jaci.2006.01.040.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.
   PubMed Web of Science ®Google Scholar
• Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282–319. •• Excellently structured guideline on all aspects of AIT including updates on studies for individual products.
   PubMedGoogle Scholar
• Brehler R, Klimek L, Vogelberg C, et al. Evidence vs. efficacy in allergen-specific immunotherapy: considerations using the example of tradable products in Germany. Allergo J Int. 2016;25:38–43. DOI:10.1007/s40629-016-0096-2 • Arguments for use of AIT products with regard to evidence versus efficacy.
   PubMedGoogle Scholar
• Cox L, Larenas-Linnemann D, Lockey RF, et al. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125(3):569–74, 74 e1–74 e7. DOI:10.1016/j.jaci.2009.10.060
   PubMed Web of Science ®Google Scholar
• Norman PS, Lichtenstein LM, Kagey-Sobotka A, et al. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol. 1982;70(4):248–260. DOI:10.1016/0091-6749(82)90061-6
   PubMed Web of Science ®Google Scholar
• Grammer LC, Shaughnessy MA, Suszko IM, et al. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol. 1983;72(5 Pt 1):448–453. DOI:10.1016/0091-6749(83)90580-8
   PubMed Web of Science ®Google Scholar
• Calderon MA, Larenas D, Kleine-Tebbe J, et al. European academy of allergy and clinical immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’. Allergy. 2011;66(10):1345–1359. DOI:10.1111/j.1398-9995.2011.02669.x. •• Systematic review on dose-response effects in AIT.
   PubMed Web of Science ®Google Scholar
• Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, et al. Local immunotherapy. Allergy. 1998;53(10):933–944. DOI:10.1111/j.1398-9995.1998.tb03793.x.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Bachert C, Bousquet PJ, et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65(12):1525–1530. DOI:10.1111/j.1398-9995.2010.02474.x.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;69(7):854–867. DOI:10.1111/all.12383. •• EAACI reccommendations for clinical outcome measures in AIT.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558–562. DOI:10.1016/S0091-6749(98)70271-4
   PubMed Web of Science ®Google Scholar
• Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41(9):1177–1200. DOI:10.1111/j.1365-2222.2011.03794.x.
   PubMed Web of Science ®Google Scholar
• GUIDELINE ON ALLERGEN PRODUCTS: PRODUCTION AND QUALITY ISSUES des COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP). EMA, London 2008.
   Google Scholar
• GUIDELINE ON THE CLINICAL DEVELOPMENT OF PRODUCTS FOR SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF ALLERGIC DISEASES des COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP). EMA, London.
   Google Scholar
• Bernstein DI, Epstein T, Murphy-Berendts K, et al. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol. 2010;104(6):530–535. DOI:10.1016/j.anai.2010.04.008
   PubMed Web of Science ®Google Scholar
• Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, et al. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87(1 Suppl 1):47–55. DOI:10.1016/S1081-1206(10)62195-3
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11(12):1321–1333. DOI:10.1586/1744666X.2015.1086645.
   PubMed Web of Science ®Google Scholar
• Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20. DOI:10.1111/j.1398-9995.2006.01219_1.x
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;132(1):93–98. DOI:10.1016/j.jaci.2013.03.039.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17. DOI:10.1186/s40413-015-0063-2 •• Excellent overview on mechanisms of AIT.
   PubMed Web of Science ®Google Scholar
• Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy. 2005;60(1):1–3. DOI:10.1111/all.2005.60.issue-1
   PubMed Web of Science ®Google Scholar
• Bousquet J, Guerin B, Dotte A, et al. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy. 1985;15(2):179–193. DOI:10.1111/j.1365-2222.1985.tb02272.x.
   PubMedGoogle Scholar
• Novak N, Mete N, Bussmann C, et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol. 2012. DOI:10.1016/j.jaci.2012.04.039.
   Web of Science ®Google Scholar
• Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2. DOI:10.1186/2045-7022-2-2
   PubMedGoogle Scholar
• Available from: http://www.pei.de/
   Google Scholar
• Backman A, Belin L, Dreborg S, et al. Standardization of allergenic preparations. Comments with reference to the second edition of the common Nordic guidelines for registration of allergenic preparations. Allergy. 1991;46(2):81–84. DOI:10.1111/j.1398-9995.1991.tb00548.x
   PubMed Web of Science ®Google Scholar
• Medicines NCo. Registration of allergenic preparations. Nordic guidelines. Uppsala, Sweden: NLN Publications; 1989.
   Google Scholar
• Turkeltaub PC, Rastogi SC, Baer H, et al. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol. 1982;70(5):343–352. DOI:10.1016/0091-6749(82)90023-9
   PubMed Web of Science ®Google Scholar
• Turkeltaub PC. Biological standardization of allergenic extracts. Allergol Immunopathol (Madr). 1989;17(2):53–65.
   PubMed Web of Science ®Google Scholar
• Chapman MD, Ferreira F, Villalba M, et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol. 2008;122(5):882–9 e2. DOI:10.1016/j.jaci.2008.07.030.
   PubMed Web of Science ®Google Scholar
• Grammer LC, Shaughnessy MA, Shaughnessy JJ, et al. Allergenicity, immunogenicity, and safety of immunotherapy with various molecular weight ranges of polymerized ragweed. J Allergy Clin Immunol. 1985;76(2 Pt 1):195–200. DOI:10.1016/0091-6749(85)90701-8
   PubMed Web of Science ®Google Scholar
• Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987;80(4):591–598. DOI:10.1016/0091-6749(87)90013-3.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Hejjaoui A, Soussana M, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol. 1990;85(2):490–497. DOI:10.1016/0091-6749(90)90160-6
   PubMed Web of Science ®Google Scholar
• Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82(3 Pt 1):439–446. DOI:10.1016/0091-6749(88)90017-6
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Kettner J, Doemer C, et al. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005;60(6):801–807. DOI:10.1111/all.2005.60.issue-6
   PubMed Web of Science ®Google Scholar
• DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32(3):239–247. DOI:10.2500/aap.2011.32.3453.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Urry Z, Robinson DS, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012;67(2):272–279. DOI:10.1111/j.1398-9995.2011.02736.x.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Robinson DS, Sager A, et al. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy. 2010;65(12):1614–1621. DOI:10.1111/all.2010.65.issue-12
   PubMed Web of Science ®Google Scholar
• Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010;126(5):942–949. DOI:10.1016/j.jaci.2010.06.002
   PubMed Web of Science ®Google Scholar
• Riechelmann H, Schmutzhard J, van der Werf JF, et al. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy. 2010;24(5):e104–9. DOI:10.2500/ajra.2010.24.3508
   PubMed Web of Science ®Google Scholar
• Rask C, Lund L, Lund G, et al. An alternative allergen: adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy. Clin Exp Allergy. 2012;42(9):1356–1368. DOI:10.1111/j.1365-2222.2012.04026.x.
   PubMed Web of Science ®Google Scholar
• Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116(3):608–613. DOI:10.1016/j.jaci.2005.06.004
   PubMed Web of Science ®Google Scholar
• Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951–960. DOI:10.1016/j.jaci.2008.09.017.
   PubMed Web of Science ®Google Scholar
• Meyer W, Narkus A, Salapatek AM, et al. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy. 2013;68(6):724–731. DOI:10.1111/all.12148
   PubMed Web of Science ®Google Scholar
• Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802–809. DOI:10.1016/j.jaci.2005.12.1358
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338–1345. DOI:10.1016/j.jaci.2007.07.046.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133(3):751–758. DOI:10.1016/j.jaci.2013.10.041.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–1725. DOI:10.1001/jama.2016.3964.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25 e5. DOI:10.1016/j.jaci.2011.12.973.
   PubMed Web of Science ®Google Scholar
• Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64(9):1394–1401. DOI:10.1111/j.1398-9995.2009.02194.x.
   PubMed Web of Science ®Google Scholar
• Valovirta E, Berstad AK, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther. 2011;33(10):1537–1546. DOI:10.1016/j.clinthera.2011.09.013.
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124(3):471–477.e1. DOI:10.1016/j.jaci.2009.06.006.
   PubMed Web of Science ®Google Scholar
• Klimek L, Kundig T, Senti G. [Allergen specific immunotherapy for rhinitis allergica: new applications]. Hno. 2015;63(5):343–351. DOI:10.1007/s00106-015-0003-z
   PubMed Web of Science ®Google Scholar
• Klimek L, Willers J, Schendzielorz P, et al. [Immunotherapy of allergic rhinitis without allergens?: new options for immunomodulation by vaccination with virus-like particles and CpG motifs]. Hno. 2013;61(10):826–833. DOI:10.1007/s00106-013-2761-9
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA. 2008;105(46):17908–17912. DOI:10.1073/pnas.0803725105.
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124(5):997–1002. DOI:10.1016/j.jaci.2009.07.019. • Early study on epicutaneous immunotherapy.
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–1296. DOI:10.1016/j.jaci.2012.02.026.
   PubMed Web of Science ®Google Scholar
• Kundig TM. Immunotherapy concepts under investigation. Allergy. 2011;66(Suppl 95):60–62. DOI:10.1111/j.1398-9995.2011.02643.x
   PubMed Web of Science ®Google Scholar
• Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71–84. •• Comprehensive review on ILIT.
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129(1):128–135. DOI:10.1016/j.jaci.2011.08.036.
   PubMed Web of Science ®Google Scholar
• Jones SM, Agbotounou WK, Fleischer DM, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137(4):1258. DOI:10.1016/j.jaci.2016.01.008.
   Web of Science ®Google Scholar
• von Moos S, Kundig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011;31(2):391–406, xi. DOI:10.1016/j.iac.2011.02.012
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy. 2011;66(6):798–809. DOI:10.1111/j.1398-9995.2011.02560.x
   PubMed Web of Science ®Google Scholar
• Senti G, Freiburghaus AU, Kundig TM. Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Curr Opin Allergy Clin Immunol. 2010;10(6):582–586. DOI:10.1097/ACI.0b013e32833f1419
   PubMed Web of Science ®Google Scholar
• Klimek L, Schmidt-Weber CB, Kramer MF, et al. Clinical use of adjuvants in allergen-immunotherapy. Expert Rev Clin Immunol. 2017;13:599–610. DOI:10.1080/1744666X.2017.1292133 •• Recent review on adjuvants in AIT.
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008;38(8):2068–2071. DOI:10.1002/eji.v38:8
   PubMed Web of Science ®Google Scholar
• Pfaar O, Cazan D, Klimek L, et al. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol. 2012;12(6):648–657. DOI:10.1097/ACI.0b013e32835a11d6
   PubMed Web of Science ®Google Scholar
• Moingeon P, Lombardi V, Saint-Lu N, et al. Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North Am. 2011;31(2):407–419. DOI:10.1016/j.iac.2011.03.001
   PubMed Web of Science ®Google Scholar
• Pfaar O, Böttcher I, Klimek L. Modulation of specific immuntherapy by adjuvants: immunological effects and clinical perspectives. Allergo J. 2009;18:261–266.
   Google Scholar
• Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy. 2005;60(5):678–684. DOI:10.1111/j.1398-9995.2005.00762.x
   PubMed Web of Science ®Google Scholar
• Stuck BA, Bachert C, Federspil P, et al. [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, head and neck surgery]. Hno. 2007;55(10):758–777. DOI:10.1007/s00106-007-1589-6.
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505. DOI:10.1034/j.1398-9995.2001.056006498.x
   PubMed Web of Science ®Google Scholar
• Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, et al. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol. 2014;133(1):121–122. DOI:10.1016/j.jaci.2013.05.032
   PubMed Web of Science ®Google Scholar
• Allam JP, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans’ cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(1):141–148. DOI:10.1067/mai.2003.1607.
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy. 2011;66(6):733–739. DOI:10.1111/j.1398-9995.2010.02535.x • Review on immunological mechanisms of SLIT.
   PubMed Web of Science ®Google Scholar
• Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol. 2008;121(2):368–374.e1. DOI:10.1016/j.jaci.2007.09.045.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Barth C, Jaschke C, et al. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol. 2011;154(4):336–344. DOI:10.1159/000321826 •• First study using MPL as an adjuvant in SLIT.
   PubMed Web of Science ®Google Scholar
• Sledge R. Treatment of hay-fever with alum-precipitated pollen. US Naval Med Bulletin. 1938;36:18.
   Google Scholar
• Pfaar O, Jung K, Wolf H, et al. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy. 2012;67(5):630–637. DOI:10.1111/j.1398-9995.2012.02801.x.
   PubMed Web of Science ®Google Scholar
• Exley C. Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. Allergy Asthma Clin Immunol. 2014;10(1):4. DOI:10.1186/1710-1492-10-4
   PubMed Web of Science ®Google Scholar
• Heydenreich B, Bellinghausen I, Konig B, et al. Gram-positive bacteria on grass pollen exhibit adjuvant activity inducing inflammatory T cell responses. Clin Exp Allergy. 2012;42(1):76–84. DOI:10.1111/j.1365-2222.2011.03888.x.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–796. DOI:10.1038/nri2868
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389(5):521–536. DOI:10.1515/BC.2008.064
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med. 2007;7(2):143–155. DOI:10.2174/156652407780059140
   PubMed Web of Science ®Google Scholar
• Yewdell JW. Designing CD8+ T cell vaccines: it’s not rocket science (yet). Curr Opin Immunol. 2010;22(3):402–410. DOI:10.1016/j.coi.2010.04.002
   PubMed Web of Science ®Google Scholar
• Tewalt EF, Grant JM, Granger EL, et al. Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. Plos Pathog. 2009;5(5):e1000457. DOI:10.1371/journal.ppat.1000457.
   PubMed Web of Science ®Google Scholar
• Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):249–258. DOI:10.1038/nri1329
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511. DOI:10.1586/erv.10.174
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943. DOI:10.1056/NEJMoa061760.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445–1455. DOI:10.1056/NEJMoa052916.
   PubMed Web of Science ®Google Scholar
• Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39(4):562–570. DOI:10.1111/j.1365-2222.2008.03191.x.
   PubMed Web of Science ®Google Scholar
• Stelmach I, Smejda K, Jerzynska J, et al. Decreased markers of atopy in children with presumed early exposure to allergens, unhygienic conditions, and infections. Ann Allergy Asthma Immunol. 2007;99(2):170–177. DOI:10.1016/S1081-1206(10)60641-2.
   PubMed Web of Science ®Google Scholar
• Braun-Fahrlander C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med. 2002;347(12):869–877. DOI:10.1056/NEJMoa020057.
   PubMed Web of Science ®Google Scholar
• Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet. 2001;358(9288):1129–1133. DOI:10.1016/S0140-6736(01)06252-3.
   PubMed Web of Science ®Google Scholar
• Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011;41(9):1305–1312. DOI:10.1111/j.1365-2222.2011.03783.x.
   PubMed Web of Science ®Google Scholar
• Norman PS, Nicodemus CF, Creticos PS, et al. Clinical and immunologic effects of component peptides in Allervax Cat. Int Arch Allergy Immunol. 1997;113(1–3):224–226. DOI:10.1159/000237553.
   PubMed Web of Science ®Google Scholar
• Pene J, Desroches A, Paradis L, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol. 1998;102(4 Pt 1):571–578. DOI:10.1016/S0091-6749(98)70294-5.
   PubMed Web of Science ®Google Scholar
• Spertini F, DellaCorte G, Kettner A, et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol. 2016;138(1):162–168. DOI:10.1016/j.jaci.2016.02.044.
   PubMed Web of Science ®Google Scholar
• Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89–97, e1–14. DOI:10.1016/j.jaci.2010.11.029.
   Web of Science ®Google Scholar